Metagenomi (MGX) Competitors $2.69 -0.16 (-5.61%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$2.77 +0.08 (+2.83%) As of 01/31/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends MGX vs. ORKA, ALLO, AURA, KOD, ESPR, CYRX, KMDA, ABVX, PRME, and VALNShould you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Oruka Therapeutics (ORKA), Allogene Therapeutics (ALLO), Aura Biosciences (AURA), Kodiak Sciences (KOD), Esperion Therapeutics (ESPR), Cryoport (CYRX), Kamada (KMDA), ABIVAX Société Anonyme (ABVX), Prime Medicine (PRME), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry. Metagenomi vs. Oruka Therapeutics Allogene Therapeutics Aura Biosciences Kodiak Sciences Esperion Therapeutics Cryoport Kamada ABIVAX Société Anonyme Prime Medicine Valneva Metagenomi (NASDAQ:MGX) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking. Do insiders and institutionals hold more shares of MGX or ORKA? 56.4% of Oruka Therapeutics shares are held by institutional investors. 22.7% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is MGX or ORKA more profitable? Oruka Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -134.27%. Oruka Therapeutics' return on equity of -24.96% beat Metagenomi's return on equity.Company Net Margins Return on Equity Return on Assets Metagenomi-134.27% -43.23% -18.86% Oruka Therapeutics N/A -24.96%-21.22% Does the MarketBeat Community believe in MGX or ORKA? Metagenomi received 6 more outperform votes than Oruka Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Oruka Therapeutics an outperform vote while only 95.00% of users gave Metagenomi an outperform vote. CompanyUnderperformOutperformMetagenomiOutperform Votes1995.00% Underperform Votes15.00%Oruka TherapeuticsOutperform Votes13100.00% Underperform VotesNo Votes Which has better earnings & valuation, MGX or ORKA? Oruka Therapeutics has lower revenue, but higher earnings than Metagenomi. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetagenomi$44.76M2.25-$68.25MN/AN/AOruka TherapeuticsN/AN/A-$5.34M-$6.26-2.15 Does the media refer more to MGX or ORKA? In the previous week, Metagenomi had 2 more articles in the media than Oruka Therapeutics. MarketBeat recorded 4 mentions for Metagenomi and 2 mentions for Oruka Therapeutics. Metagenomi's average media sentiment score of 1.09 beat Oruka Therapeutics' score of 0.63 indicating that Metagenomi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend MGX or ORKA? Metagenomi currently has a consensus target price of $16.67, indicating a potential upside of 519.58%. Oruka Therapeutics has a consensus target price of $43.17, indicating a potential upside of 220.94%. Given Metagenomi's higher probable upside, equities research analysts plainly believe Metagenomi is more favorable than Oruka Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 SummaryOruka Therapeutics beats Metagenomi on 9 of the 15 factors compared between the two stocks. Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGX vs. The Competition Export to ExcelMetricMetagenomiBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.17M$3.08B$5.57B$9.20BDividend YieldN/A1.84%5.31%3.99%P/E RatioN/A22.5264.1014.76Price / Sales2.25425.051,272.7791.55Price / CashN/A190.0245.9637.70Price / BookN/A4.125.124.71Net Income-$68.25M-$40.99M$111.17M$224.24M7 Day Performance-9.43%-0.44%2.38%-0.17%1 Month Performance-25.48%0.93%3.20%0.60%1 Year PerformanceN/A-1.69%24.70%20.43% Metagenomi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGXMetagenomi1.7869 of 5 stars$2.69-5.6%$16.67+519.6%N/A$99.17M$44.76M0.00236ORKAOruka Therapeutics2.4616 of 5 stars$11.46-6.0%$43.17+276.7%N/A$403.38MN/A-1.84N/AUpcoming EarningsALLOAllogene Therapeutics2.8348 of 5 stars$1.92-1.3%$9.73+408.3%-48.9%$401.52M$90,000.00-1.23310AURAAura Biosciences2.8096 of 5 stars$7.98+1.1%$23.00+188.4%+1.9%$399.61MN/A-4.6250Analyst UpgradeShort Interest ↑News CoverageKODKodiak Sciences3.6012 of 5 stars$7.55-5.7%$8.00+6.0%+59.6%$397.28MN/A-2.0790Short Interest ↑Gap DownESPREsperion Therapeutics4.175 of 5 stars$2.02-4.0%$7.25+259.8%-16.4%$397.04M$116.33M-3.15200Short Interest ↑CYRXCryoport3.5966 of 5 stars$8.03+0.2%$12.29+53.1%-48.0%$396.43M$233.26M-2.371,170Short Interest ↓KMDAKamada4.5076 of 5 stars$6.89-4.2%$14.50+110.5%+17.5%$395.87M$142.52M24.60360Short Interest ↑Gap DownABVXABIVAX Société Anonyme2.2765 of 5 stars$6.15+1.0%$38.67+528.7%-54.7%$390.87MN/A0.0061PRMEPrime Medicine3.7575 of 5 stars$2.97-5.7%$13.13+341.8%-55.9%$390.73MN/A-1.45234News CoverageVALNValneva2.0401 of 5 stars$4.79-2.2%$17.50+265.3%-29.1%$389.65M$158.54M-36.88700Analyst ForecastShort Interest ↓News CoverageGap Down Related Companies and Tools Related Companies Oruka Therapeutics Competitors Allogene Therapeutics Competitors Aura Biosciences Competitors Kodiak Sciences Competitors Esperion Therapeutics Competitors Cryoport Competitors Kamada Competitors ABIVAX Société Anonyme Competitors Prime Medicine Competitors Valneva Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MGX) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
